Literature DB >> 11371761

Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?

C L Karp1, A H van Boxel-Dezaire, A A Byrnes, L Nagelkerken.   

Abstract

Interferon-beta is a remarkably pleiotropic molecule. Antiviral, pro- and antiproliferative, pro- and antiapoptotic, and complex immunoregulatory activities have all been described. The precise mechanism(s) that underlie the beneficial effects of interferon-beta in multiple sclerosis remain poorly understood; this has hindered progress in the search for more effective therapies. An increasing body of literature supports the hypothesis that interferon-beta-mediated changes in the production and activities of the immunoregulatory cytokines interleukin-12 and interleukin-10 are important to the therapeutic benefits of interferon-beta in multiple sclerosis. These data are reviewed here.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11371761     DOI： 10.1097/00019052-200106000-00016

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN： 1350-7540            Impact factor:   5.710


  10 in total

1.  IFN-β mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis.

Authors:  Timothy J Bauler; Jennifer C Chase; Catharine M Bosio
Journal:  J Immunol       Date:  2011-07-13       Impact factor: 5.422

2.  Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.

Authors:  A Tamir; W J Jordan; M Ritter; N Habib; R I Lechler; G R Foster; G Lombardi
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 3.  Interferon-beta treatment for multiple sclerosis.

Authors:  Robert A Bermel; Richard A Rudick
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 4.  Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis.

Authors:  Tanuja Chitnis; Samia J Khoury
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  IL-2 suppression of IL-12p70 by a recombinant HSV-1 expressing IL-2 induces T-cell auto-reactivity and CNS demyelination.

Authors:  Mandana Zandian; Kevin R Mott; Sariah J Allen; Shuang Chen; Moshe Arditi; Homayon Ghiasi
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

6.  Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing IL-2.

Authors:  M Zandian; K R Mott; S J Allen; O Dumitrascu; J Z Kuo; H Ghiasi
Journal:  Gene Ther       Date:  2011-03-17       Impact factor: 5.250

7.  Interferon-β suppresses murine Th1 cell function in the absence of antigen-presenting cells.

Authors:  Nicolas Boivin; Joanie Baillargeon; Prenitha Mercy Ignatius Arokia Doss; Andrée-Pascale Roy; Manu Rangachari
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

8.  A comparative study of experimental mouse models of central nervous system demyelination.

Authors:  O M Dumitrascu; K R Mott; H Ghiasi
Journal:  Gene Ther       Date:  2014-04-10       Impact factor: 5.250

9.  Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.

Authors:  Chiara D'Angelo; Marcella Reale; Erica Costantini; Marta Di Nicola; Italo Porfilio; Clara de Andrés; Lidia Fernández-Paredes; Silvia Sánchez-Ramón; Livia Pasquali
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

10.  CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.

Authors:  Soraya Maria Menezes; Daniele Decanine; David Brassat; Ricardo Khouri; Saul V Schnitman; Ramon Kruschewsky; Giovanni López; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Anne-Mieke Vandamme; Bernardo Galvão-Castro; Roland Liblau; Johan Van Weyenbergh
Journal:  J Neuroinflammation       Date:  2014-01-29       Impact factor: 8.322
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.